SHIM
CAPR icon

Stone House Investment Management’s Capricor Therapeutics CAPR Stock Holding History

Stone House Investment Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433 Sell
18
-15
-45% -$455 ﹤0.01% 1050
2026
Q1 		$1K Buy
+33
New +$879 ﹤0.01% 694

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stone House Investment Management's CAPR Position: Q2 2026 in Review

Stone House Investment Management reduced its Capricor Therapeutics (CAPR) stake by 45% in Q2 2026, selling an estimated $455 and leaving 18 shares worth $433. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Stone House Investment Management first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Stone House Investment Management held 18 shares of Capricor Therapeutics worth $433 as of Q2 2026.
  • Stone House Investment Management sold 15 Capricor Therapeutics shares in Q2 2026, an estimated $455.
  • Capricor Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1050 holding.
  • Stone House Investment Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Stone House Investment Management's Capricor Therapeutics position peaked at $1K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.